No abstract available.

No abstract available.

No abstract available.

No abstract available.

No abstract available.
Ear, Middle*

No abstract available.
Ear, Middle* ; Eustachian Tube*

Adult-onset egg allergy is rare compared to child-onset egg allergy, and the component-resolved diagnosis test is effective in evaluating food allergy. We herein report a 24-year-old woman with late-onset egg-yolk allergy diagnosed as bird-egg syndrome. The prolonged exposure to pet parrots' dander or dropping through the respiratory system caused sensitization to the Gal d 5 component and resulted in a cross-reaction to egg yolk. Since the patient was suspected of the syndrome by her history, the skin prick test, ISAC ImmunoCAP, and serum ImmunoCAP test were performed. By confirming Gal d 5 component by ISAC ImmunoCAP, the patient was diagnosed with the syndrome. In patients with newly adult-onset food allergy, the clinician must identify the environmental conditions which can cause cross-sensitization and perform the causative component test.

Vascular endothelial cell expression of avb3, and integrin receptor that binds von Willebrand factor, vitronectin, and fibrinogen, increases in response to angiogenic stimuli such as basic fibroblast growth factor(bFGF) and during capillary proliferation in vivo. We investigated the importance of avb3 function during bFGF-induced corneal angiogenesis by examining the effects of 9D491, a monoclnal natibody against b3 that blocks avb3-mediated cell adhesion to vitronectin and fibrinogen in vitro. A hydrogel disk containing 500ng of bFGF was implanted into the superior corneal stroma of each of twelve New Zealand white rabbit eyes. Each eye also received a second hydrogel disk placed adjacent of the firtt, randomized to contain either 3ug of 9D491 mAb(n=6) or 6E10, an irrelevant antibody of the same isotype, (n=6). Both disks were positioned 1.2mm from the superior limbus. Eyes were examined daily under a streomicroscope by two masked observers and counted an angiogenesis score based on number and length of new blood vessels. On days 5 through 7 post-implantation, angiogenesis scores were significantly lower in eyes treated with avb3 mAb(averaged score=3.3) as compared to eyes treated with 6E10(averaged score=8.0)(p<0.002, Wilcoxon rank sum test). In a rabbit corneal pocket model of angiogenesis, neutralizing monoclonal antibody to b3 inhibits corneal angiogenesis induced by bFGF. Substances that target the integrin b3 subunit may have therapeutic potential in disorders characterized by ocular neovascularization.
Blood Vessels ; Capillaries ; Cell Adhesion ; Corneal Neovascularization* ; Corneal Stroma ; Endothelial Cells ; Fibrinogen ; Fibroblasts ; Hydrogel ; Masks ; New Zealand ; Vitronectin ; von Willebrand Factor

Vascular endothelial cell expression of avb3, and integrin receptor that binds von Willebrand factor, vitronectin, and fibrinogen, increases in response to angiogenic stimuli such as basic fibroblast growth factor(bFGF) and during capillary proliferation in vivo. We investigated the importance of avb3 function during bFGF-induced corneal angiogenesis by examining the effects of 9D491, a monoclnal natibody against b3 that blocks avb3-mediated cell adhesion to vitronectin and fibrinogen in vitro. A hydrogel disk containing 500ng of bFGF was implanted into the superior corneal stroma of each of twelve New Zealand white rabbit eyes. Each eye also received a second hydrogel disk placed adjacent of the firtt, randomized to contain either 3ug of 9D491 mAb(n=6) or 6E10, an irrelevant antibody of the same isotype, (n=6). Both disks were positioned 1.2mm from the superior limbus. Eyes were examined daily under a streomicroscope by two masked observers and counted an angiogenesis score based on number and length of new blood vessels. On days 5 through 7 post-implantation, angiogenesis scores were significantly lower in eyes treated with avb3 mAb(averaged score=3.3) as compared to eyes treated with 6E10(averaged score=8.0)(p<0.002, Wilcoxon rank sum test). In a rabbit corneal pocket model of angiogenesis, neutralizing monoclonal antibody to b3 inhibits corneal angiogenesis induced by bFGF. Substances that target the integrin b3 subunit may have therapeutic potential in disorders characterized by ocular neovascularization.
Blood Vessels ; Capillaries ; Cell Adhesion ; Corneal Neovascularization* ; Corneal Stroma ; Endothelial Cells ; Fibrinogen ; Fibroblasts ; Hydrogel ; Masks ; New Zealand ; Vitronectin ; von Willebrand Factor

Vascular cells respond to multiple cytokines, they also express a variety of integrin adhesion receptor. A number of the vascular cell integrins are functionally and structurally homologous, suggesting some level of biologic redundancy. We investigated the importance of alphavbeta3 function during vascular endothelial growth factor(VEGF) induced corneal angiogenesis by examining the effects of 9D491, a monoclonal antibody against beta3 that blocks alphavbeta3-mediated cell adhesion to vitronectin and fibrinogen. A hydrogel disk containing 500ng of VEGF was implanted into the superior corneal stroma of each of twelve New Zealand white rabbit eyes. Each eye also received a second hydrogel disk placed adjacent of the first, randomized to contain either 2.6microgram of 9D491 mAb(n=6) or 6E10, an irrelevant antibody of the same isotype, (n=6). Both disks were positioned 1.2mm from the superior limbus. Eyes were examined daily under a streomicroscope by two masked observers and assigned an angiogenesis score based on number and length of new blood vessels. On days 5 through 7 postimplantation, angiogenesis scores were not significantly lower in eyes treated with anti-alphavbeta3 mAb (averaged score=21.6) as compared to eyes treated with 6E10 (averaged score=24.0) (p<0.2, Wilcoxon rank sum test). In a rabbit corneal pocket assay, monoclonal antibody to beta3 could not inhibit corneal angiogenesis induced by VEGF.
Blood Vessels ; Cell Adhesion ; Corneal Neovascularization* ; Corneal Stroma ; Cytokines ; Fibrinogen ; Hydrogel ; Integrin beta3 ; Integrins ; Masks ; New Zealand ; Vascular Endothelial Growth Factor A* ; Vitronectin